Back to today’s briefing

Story perspectives

Novo Nordisk Cuts Wegovy Price Amid FDA Changes

6/3/2025

43 6

Summary

Story summary

Novo Nordisk has slashed Wegovy's price after the FDA ended the grace period for compounded GLP-1 drugs, a move that could reshape access to weight-loss medications. While the FDA's decision may drive up prices for commercial options, compounding pharmacies might step in with affordable alternatives, enhancing accessibility for patients seeking help.

1 of 1

Story summary

Novo Nordisk has slashed Wegovy's price after the FDA ended the grace period for compounded GLP-1 drugs, a move that could reshape access to weight-loss medications. While the FDA's decision may drive up prices for commercial options, compounding pharmacies might step in with affordable alternatives, enhancing accessibility for patients seeking help.